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INTRODUCTION
The dry eye syndrome is one of the most prevalent diseases
of the eye that affects approximately 10% to 20% of adult
population (1). Dry eye develops from multiple etiologies such
as a tear deficiency, abnormal evaporation, surface inflamma-
tion and abnormal neural regulation (2). The most common
medical treatments for dry eye are currently artificial tear su-
pplementation, immune suppression with medications such
as cyclosporine A (3), and hyaluronic acid (HA) (4) which pr-
omotes epithelial healing.
Recently, the role of the P2Y2 receptor agonist on dry eye
has been investigated in vitro and in vivo (5-7). Topical admin-
istration of uracil-cytosine dinucleotide denufosol (Diquafosol)
is currently undergoing clinical trials for dry eye disease (8).
Uridine is transformed to UTP (uridine 5-triphosphate) by
uridine kinase in vivo after administration. UTP, as a P2Y2
receptor agonist, is known to stimulate mucin secretion in
vitro and in vivo in conjunctiva, which increases tear film sta-
bility and protects against desiccation of the ocular surface
(9, 10).
In our previous study, we showed that topical uridine could
restore the health of the ocular surface in a rabbit corneal wo-
und and dry eye model (11). Furthermore, elevated uridine
5′ -diphosphate (UDP)-glucose has been shown to contribute
to an increase in the synthesis of intrinsic HA (12, 13). Hence,
oral uridine may help patients with dry eye by increasing tear
secretion or hyaluronic acid. In fact, oral uridine is currently
used as a dietary supplement and is commercially available.
Recently, the concept of dry eye has been changed to focus
on the importance of dysfunctional tears. The Delphi panel
reported on the crucial role of the symptoms as well as the
clinical signs for the diagnosis of the dysfunctional tear syn-
drome (13). Even without any sign of a damaged ocular sur-
face, complaints of dryness or a foreign body sensation can be
diagnosed as the dysfunctional tear syndrome based on the
guidelines provided by the Delphi panel committee (14-16).
Therefore, the aim of the present study was to investigate
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Preliminary Effects of Oral Uridine on the Ocular Surface in Dry Eye
Patients
We designed a randomized, double blinded, 3-months controlled prospective clini-
cal study to investigate effects of oral uridine on the ocular surface in dry eye pati-
ents. Twenty-seven patients who diagnosed as dry eye with lower than 5 mm of
wetting in the Schirmer strip, with corneal epithelial erosion and who completely
followed-up till 3 months were enrolled. Corneal-conjunctival fluorescein staining,
non-anesthetic Schirmer test, impression cytology, and Ocular Surface Disease
Index (OSDI) were evaluated in the experimental and placebo groups at the base-
line, 1 and 3 months after start of medication in a double blinded manner. Fluores-
cein stain score of the cornea was markedly decreased in oral uridine group com-
pared to the placebo group at 3 months after medication (P=0.032, Mann-Whitney
U test). The Schirmer wetting score for the oral uridine group was significantly inc-
reased (P=0.001, Wilcoxon signed rank test) at 3 months and its difference between
two groups was statistically significant (P=0.030, Mann-Whitney U test). OSDI scores
were significantly decreased at 1 and 3 months in treatment group. Oral uridine is
effective in treatment of dry eyes.
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Accepted : 25 October 2008the effect of oral uridine on the ocular surface in dry eye pa-
tients, by evaluating the clinical signs and symptoms with
the Ocular Surface Disease Index (OSDI).
MATERIALS AND METHODS
Patient selection
The study was approved by the institutional review board
of Seoul National University Hospital and written consent
was obtained from each patient before participation; the study
protocol followed the guidelines of the Declaration of Helsin-
ki. Patients who were diagnosed with bilateral dry eye syn-
drome, showing lower than 5 mm of wetting with the Sc-
hirmer strip, superficial punctate keratitis and no improve-
ment despite the use of any prescribed medications for at least
2 months in their both eyes were recruited from the Seoul
National University Hospital from May 2005 to May 2006.
The patients were initially enrolled in a randomized, dou-
ble-blinded, 3-month, controlled clinical study. ‘No improve-
ment’ was defined as a case that despite previsously prescribed
medications, patient showed no change in their symptoms,
Schirmer test and fluorescein score for more than 2 months.
Subjects were excluded if they had any of the following:
dry eye caused by Stevens-Johnson syndrome or cicatricial
pemphigoid, a history of intraocular surgery or corneal surgery
such as LASIK, or corneal transplant before enrollment. In
addition, patients with neurotrophic keratitis, ongoing ocu-
lar infection such as a significant blepharitis, herpes infection,
or bacterial keratitis were excluded. Furthermore, if the sub-
jects could not complete a 3-month follow-up or take their
medications accurately, they were excluded.
If they had any of new systemic symptoms after taking me-
dication such as indigestion, diarrhea, we recommended them
to stop taking medications.
Treatment
Patients were randomly assigned to 3-months of treatment
with oral uridine (HALUTECH plus
�, KFDA, No.2004-
0060-047, 800 mg/tab, MDbioalpha, Daejeon, Korea) or
placebo, 2 tablets 3 times a day. The placebo was composed
of L-glutamine, lactose and crystalline cellulose which was
the same color and shape as HALUTECH plus
�but contained
no uridine. HALUTECH plus
� which was developed for de-
generative arthritis, included 50 mg of uridine in its one ta-
blet. The patients were allowed to use their all previously
prescribed medications except for the hyaluronic acid eye
drops for minimizing the possible confounding effects. The
treatment medication or placebo was given to the patients
by the medical assistant who was not involved in the evalu-
ation of the patients.
Evaluation 
All tests were performed in the experimental and placebo
groups at the baseline, 1 and 3 months after the start of the
study medication in a double-blinded manner.
OSDI was used for the evaluation of the subjective patient
symptoms (17). The patients answered the 12 items on the
OSDI questionnaire that were graded on a scale of 0 to 4 (0:
none of the time, 1: some of the time, 2: half of the time, 3:
most of the time, 4: all of the time). The OSDI was calcu-
lated by ([sum of scores for all questions answered]×100)/
([total number of questions answered]×5). The ophthalmo-
logic examination included, in the following order: corneal
fluorescein staining, a non-anesthetic Schirmer test and im-
pression cytology. The corneal staining was examined with
a slit lamp biomicroscope in cobalt blue light 3 min after
fluorescein instillation. Punctate staining was recorded with
a standardized grading system of 0 to 9. The corneal and con-
junctival surface was divided into nine areas, and the num-
bers from each of the nine stained divisions were added (20).
For the Schirmer (I) test, Schirmer strip was inserted over the
lower lid margin into the cul-de-sac in the temporal one-third
of the lid without topical anesthesia. The strip is removed at
5 min and the extent of wetting of the strip was measured.
Conjunctival impression cytology was performed as follows
(22). After topical anesthesia with Alcaine
� (0.5% propara-
caine hydrochloride, Alcon-Couvreur, Puurs, Belgium), MF
Millipore membrane filters with a pore size of 0.22 μ m were
applied onto the temporal bulbar conjunctiva. The membrane
filter was cut into 5×5 mm asymmetrical pieces with a poi-
nted tip in one corner to guarantee the correct staining sur-
face. With an ophthalmodynamometer, a gentle pressure of
60 g was applied onto the micropore filter membrane for 5
sec. Then, the membrane was fixed in 95% ethanol, stained
with periodic acid-Schiff, dehydrated in ethanol (70, 80, 90,
100% in sequence), and next with xylene, and, finally cov-
erslipped. Goblet cells were counted in 10 consecutive high-
power fields (HPFs, ×400). Three observers, who were blind-
ed to the patient treatment, performed all pre- and post-treat-
ment evaluations. Each observer separately examined each
test (fluorescein staining, Schirmer test and impression cytol-
ogy). Another observer who was not involved in any other
examination counted the goblet cells.
Statistics
Within each group, the changes in tear secretion, corneal
staining, OSDI, and goblet cell counts before and after treat-
ment were compared using a Wilcoxon signed-rank test. To
compare the outcome between the groups, we used the Mann-
Whitney U test with ratios of the values at 1 and 3 months
compared to the values at baseline for minimizing the statis-
tical error caused by individual variation. To know the cor-
relation and difference between right and left eye within each
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Whitney U test were used. P<0.05 was considered statistical-
ly significant. Statistical analysis was performed using SPSS
14.0 for Windows (SPSS Inc, Chicago, IL, U.S.A.).
RESULTS
Forty-one patients were initially enrolled and randomly
assigned to the medication or placebo group. Fourteen pati-
ents were excluded from the analysis because they did not
complete the 3-month follow-up. The main reasons for the
drop-off were mild gastrointestinal symptoms and poor com-
pliance. Among the 27 patients who completed the trial, 30
eyes of 15 patients were in the oral uridine group and 24 eyes
of 12 patients were in the placebo group. There were 3 men
and 24 women, with a mean (±SD) age of 55 (±15.22) yr
(range, 13-76). All patients in both groups showed a mod-
erate to severe dry eye and their previously prescribed medi-
cations included preservative-free artificial tear, topical 0.05%
cyclosporine (Restasis
�, Allergan Inc., Irvine, CA, U.S.A.),
autologous serum, and teramycin oint. They used no systemic
medication for their dry eye.
Corneal and conjunctival fluorescein staining
For the oral urdine treatment group, the post-treatment
corneal fluorescein staining scores, after 1 and 3 months of
medication, were significantly lower than those obtained at
the baseline (P=0.004 and P<0.001 for 1 and 3-months of
medication, Wilcoxon signed rank test). This reduction was
significantly lower in the placebo group (P=0.070 and 0.117
for 1 and 3-months of medication, Wilcoxon signed rank
test) (Fig. 1A). The fluorescein staining score was markedly
decreased in the oral uridine group compared to the placebo
group at 3-months after treatment (P=0.032, Mann-Whit-
ney U test) (Fig. 2A). There was a moderate correlation (oral
uridine group, ρ =0.449 (P=0.093) and 0.607 (P=0.016) for
1 and 3-months of medication; placebo group, ρ =0.751 (P=
0.008) and 0.653 (P=0.029) for 1 and 3-months of medica-
tion) and no significant difference between right and left eye
within each both group (oral uridine group, P=0.642 and
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Fig. 1. Change within each group of oral uridine and placebo in conjunctival and corneal fluorescein staining (A), aqueous tear production
(B), conjunctival goblet cell density (C) and Ocular Surface Disease Index (OSDI) (D). Data are expressed as mean±SD.
*P<0.01; 
� P=0.044 (Wilcoxon signed rank test).
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Fig. 2. Change of ratio of the values at 1 and 3 months of treatment to the values at baseline of treatment. This is for comparison of effica-
cy between two groups in conjunctival and corneal fluorescein staining (A), aqueous tear production (B), conjunctival goblet cell density
(C) and Ocular Surface Disease Index (OSDI) (D). Data are expressed as meanmean±SD.*P=0.032; 
� P=0.030 (Mann-Whitney U test).
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0.439 for 1 and 3-months of medication; placebo group, P=
0.946 and 0.606 for 1 and 3-months of medication). 
Aqueous tear production
The Schirmer wetting score for the oral uridine group was
significantly increased (P=0.001, Wilcoxon signed rank test),
compared with that for the placebo group (P=0.334, Wilcox-
on signed rank test) at 3-months after treatment (Fig. 1B).
The difference between the inter-group ratios between the
treatment and control group at 3-months after treatment
was also significant (P=0.030, Mann-Whitney U test) (Fig.
2B). There was a moderate correlation between right and left
eye in oral uridine group (ρ =0.904 [P<0.001]) and 0.563 (P=
0.023) for 1 and 3-months of medication) but not in place-
bo group (ρ =0.362 [P=0.274] and 0.278 [P=0.409]) for 1
and 3-months of medication. There was no significant dif-
ference between right and left eye within each both group
(oral uridine group, P=0.776 and 0.821 for 1 and 3-months
of medication; placebo group, P=0.365 and 0.478 for 1 and
3-months of medication). 
Conjunctival goblet cell density
The goblet cell density, for the oral uridine treatment gr-
oup, at 1 and 3-months increased; however, the differences
were not significant at 1 month (P=0.660, Wilcoxon signed
rank test) and showed only marginal significance at 3-months
(P=0.053, Wilcoxon signed rank test) (Fig. 1C). The differ-
ence between the oral uridine and placebo group, for con-
junctival goblet cell density, at 1 and 3-months after treat-
ment was not significant (P=0.802 and 0.201 for 1 and 3
months of medication, Mann-Whitney U test) (Fig. 2C). 
Ocular surface disease index
The OSDI was significantly decreased in the oral uridine
group at 1 and 3-months (P=0.004 and P=0.044 fort 1 and
3-months of medication, Wilcoxon signed rank test) (Fig. 1D).
The change of OSDI in control group after placebo-treatment
looked like improved, but it was not significant. However,
the difference in the ratios between the two groups, up to 3-
months, was not significant (P=0.506 and 0.838 for 1 and3-months of medication, Mann-Whitney U test) (Fig. 2D).
Side effects of the drug
The most common treatment-related adverse events were
gastrointestinal symptoms. Six (four in the oral uridine group,
and two in the placebo group) of 14 patients were dropped
out from the trial because they complained of mild gastroin-
testinal symptoms such as dyspepsia (n=3), indigestion (n=1)
and abdominal discomfort (n=2). After treatment discon-
tinued, the symptoms resolved. No treatment-related seri-
ous adverse events occurred during the study. 
DISCUSSION
The objective of the present study was to evaluate the effi-
cacy of oral uridine for treatment of the ocular surface in dry
eye patients. The results of this study showed that oral uri-
dine treatment had a greater effect on improving the tear
production and reducing corneal fluorescein staining than did
the placebo. 
The tear production for the oral uridine group was signif-
icantly increased, compared with that for the placebo group
at 3-months after treatment. This result of the present study
correspond with the previous studies which P2Y receptor
agonists such as UTP stimulate active Cl-transport across
the excised rabbit conjunctival tissue in vitro (24) and increase
tear production in rabbits (25).
The finding of a decrease of corneal staining after the ad-
ministration of oral uridine was consistent with the results
of our previous study. Previously, we demonstrated that the
topical application of uridine enhanced healing of a corneal
epithelial defect in a rabbit dry eye model. These findings
were thought to be associated with the increased biosynthesis
of hyaluronate and glycosaminoglycan, or the reduction of
MMP-9 by uridine as described in our previous study (11).
The effect of oral uridine, on the goblet cell counts, appears
to be different from our earlier study showing a definite in-
crease in the goblet cells with topical uridine. Some possible
explanations for these differences are the following. The pre-
vious study used rabbit eyes with artificially induced dry eye.
The rabbit is well known for proliferation of epithelial (21)
or endothelial cells (22, 23) after damage. The goblet cells
of rabbits are more rapidly restored after an insult than they
are in humans. Another consideration is the difference of se-
verity in dry eye between humans and the rabbits. A dried
ocular surface in the rabbits was established by a transient
decrease of tear secretion after lacrimal inflammation for 10
days. However, many different factors are involved in the de-
velopment of dry eye in humans. In addition, the presence
of dry eye in the patients was much longer than in the rab-
bits. Our results showed that the goblet cells tended to grad-
ually increase until 3-months after the start of treatment with
a marginal significance when compared to the placebo group.
We found that oral uridine treatment was associated with
a reduced OSDI. Since the subjective symptoms of dysfunc-
tional tear syndrome are used as diagnostic criteria, our results
suggest that this treatment may be helpful for patients with
dysfunctional tear syndrome even without signs of damage
to the ocular surface. Treatment with oral uridine significant-
ly improved the subjective symptoms of dry eye. However,
placebo group also showed some reduction of OSDI which
turned out to be insignificant and was assumed to be caused
by “placebo-effect”. It might affect the result which present-
ed no significant difference between those groups. To clarify
that issue, large number of prospective study is pending.
Diquafosol tetrasodium (INS365) (8), has also demonstrat-
ed improvement in tear production in randomized, controlled
ongoing clinical trials. Diquafosol, a P2Y2 receptor agonist,
which is an analogue of the endogenous compound UTP, is
thought to contribute to the restoration of the normal integri-
ty of the ocular surface by promoting fluid and mucin secre-
tion, regardless of lacrimal gland function (24, 25). Uridine
is transformed to UDP or UTP by uridine kinase in vivo. In
a similar manner to diquafosol, the results of our study showed
that uridine has a similar effect on the ocular surface, as does
the P2Y2 receptor agonist. Furthermore, uridine administra-
tion appears to induce cross-talk for the synthesis of hyalu-
ronate, as discussed in our previous study (11). Several other
studies showed elevated UDP-glucose with the synthesis of
hyaluronic acid (12, 13). Therefore, oral uridine may have a
dual role, the increase of hyaluronic acid synthesis and as a
P2Y2 receptor agonist, possibly resulting in restoration of
healthy ocular surface including increase of goblet cells. 
Meanwhile, several studies showed that repeated exposure
with purinergic agonist such as UTP causes receptor desen-
sitization in vitro (26-28). Therefore, adequate frequency and
dosage of UTP derivatives to avoid desensitization seems to
be crucial for being effective on ocular surface in dry eye pa-
tients. Although we found application of uridine 3 times a
day (300 mg/day) for 3 months is likely to be working on
ocular surface, we do not know the optimal frequency and
dosage of uridine to maximize the effect and whether long
term application of daily dosage may induce desensitization
or not. Further study would be warranted to evaluate desen-
sitization.
The effects of oral uridine seemed to be more prominent
at 3-months of treatment than at 1-month. Although uri-
dine has been used as a therapeutic agent in the treatment
of several other medical disorders (29-31), we do not know
the precise bioavailiability of the uridine which we provid-
ed to the patients. Regarding the clinical use of oral uridine
has been limited by its poor oral bioavailability (7-8%) and
short plasma elimination half-life (32, 33), further investi-
gation of its bioavailability is needed to improve these limi-
tations.
In order to determine the exact mechanism of action of
Effects of Oral Uridine on Dry Eyes  705oral uridine on the ocular surface and proper dosage for dry
eye, another study on the relationship between the expression
of hyaluronan synthase (HAS) or the P2Y2 receptor with ad-
ministration of oral uridine, in an in vivo model, is currently
under way. 
For the safety of oral uridine, prior uridine studies (32-34)
using high doses of oral uridine or uridine prodrugs have
shown the drug to be well tolerated in humans; osmotic diar-
rhea sometimes has been reported as dose-limiting and uri-
dine is now commercially available as sugarcane extracts in
the world. In our study there were also several patients having
mild gastrointestinal symptom after medication. Of them,
four patients belong to oral uridine group and two belong
to placebo group. In fact, the uridine which we used was not
a pure uridine but a combination with other components
including L-glutamine, lactose and crystalline cellulose. The-
refore, gastrointestinal symptom might be possibly caused by
other components as well as uridine. These side effects were
mild and resolved after discontinuation of the medication. 
This study has several limitations. First, the small num-
ber of patients was enrolled. A larger randomized clinical
trial is required to confirm the safety and efficacy of oral uri-
dine. Second, the tear secretion was measured by the Schirmer
test, which has been criticized for its variability and low sen-
sitivity (18). However, it is still a useful way of measuring
the aqueous tear production; it is a simple test, with low cost
and wide availability, and it has been used in many clinical
studies on dry eye. Like other studies, Schirmer I test (with-
out topical anesthesia) was also used in our study. Schimer I
test better reflects the reflex tearing and ocular surface abnor-
malities in patients with dry eye as compared to the schirmer
test with anesthesia because the reflex tearing is important
for the maintenance of the ocular surface (35). Third, the de-
sign of the study was, at some point, limited because the pa-
tients had been allowed to keep their most previously pre-
scribed topical eyedrops except the hyaluronic acid eye drops.
Because the patients suffered from intractable dry eyes even
though all those medication, ethically we could not stop giv-
ing them those drops. We admit those differences of topical
medication between treated and control groups may have a
confounding effect on analyzing the influence of oral uridine.
However, we did not directly compare treated group with
control group. Considering that the changes of post-treated
eye from the pre-treated were indirectly compared using the
ratio in each group, we still believe this study shows clinical
relevance in some extent. 
Despite several limitations, to the best of our knowledge,
this is the first study showing that oral uridine may be help-
ful for patients with moderate-to-severe dry eye syndrome at
least for 3 months. 
The results of this study showed that the administration
of oral uridine was likely to be safe and effective; it increased
tear secretion, decreased fluorescein staining of the damaged
cornea and improved patient subjective symptoms.
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